TriSalus Life Sciences lays out therapeutic strategy upon acquisition of first therapeutic candidate

TriSalus Life Sciences lays out therapeutic strategy upon acquisition of first therapeutic candidate

DENVER and CHICAGO -- TriSalus Life Sciences (TriSalus), an emerging immune-oncology company committed to transforming outcomes for patients with solid tumors, announced its therapeutic clinical... Read More

Monday September 28, 2020 0 comments Tags: Westminster, TriSalus Life Sciences, SD-101, Mats Wahlstrom, Mary Szela, Steven Katz